A Phase 1B/2, Open-label Study of Q702 in Combination With Intravenous Pembrolizumab in Patients With Selected Advanced Solid Tumors
Description
Brief Summary
This study is a phase 1B/2 open-label, study to determine safety and preliminary efficacy of
Q702 in combination with pembrolizumab in study subjects with advanced esophageal,
gastric/GEJ, hepatocellular, and cervical cancers.
Phase
N/AInclusion and Exclusion Criteria
- - The participant (or legally acceptable representative if applicable) provides written informed consent for the trial. - Subjects with histologically or cytologically confirmed advanced or metastatic esophageal, gastric/GEJ, hepatocellular and cervical cancers who have progressed on treatment with an anti-PD1 or anti PD-L1 monoclonal antibody (mAb) administered either as monotherapy, or in combination with other therapies
- as assessed by local site investigator/radiology - Have an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 - Life expectancy of at least 3 months
- A WOCBP who has a positive urine pregnancy test (within 72 hours) prior to treatment or breast-feeding women
- Concomitant use of strong inhibitors and inducers of CYP1A2, 2J2, 2C19, 2D6, and 3A4/5 within the timeline duration of five half-lives prior to starting study drug and throughout the trial
- Concomitant use of sensitive substrates of CYP2C9, 2C19, and 3A4 within the timeline duration of five half-lives prior to starting study drug and throughout the trial
- Has received prior radiotherapy within 2 weeks of start of study treatment or have had a history of radiation pneumonitis
- Has had an allogeneic tissue/solid organ transplant
Sites
Please contact the trial administrator to learn more about where you can participate in this trial. Please use the contact form on the right side.
Powered by
SC CTSI